Fetal Lung Drainage Saves Two-Thirds of Babies With Fluid-Filled Chests, Major Review Finds

A tiny silicone coil threaded through a needle into the chest of an unborn baby can save roughly two out of three fetuses suffering from a rare but potentially deadly condition, according to the most comprehensive analysis of the procedure to date. The systematic review and meta-analysis, published in the journal Advances in Therapy, pooled data from ten retrospective cohort studies covering 416 fetuses treated with pleuro-amniotic shunting for isolated pleural effusion, a condition in which fluid accumulates in the space surrounding the developing lungs. The findings offer the clearest quantitative picture yet of both the promise and the price of one of fetal medicine’s most delicate interventions, arriving at an overall survival rate of 65.36 percent and a hydrops resolution rate of 62.25 percent, alongside sobering figures for preterm birth and membrane complications.

Fetal pleural effusion is an accumulation of fluid within the pleural space, the thin cavity that surrounds each lung. It is rare, affecting an estimated one in 10,000 to one in 15,000 pregnancies, and it can appear as an isolated primary condition or as a secondary feature of chromosomal abnormalities, genetic syndromes, congenital infections, heart defects, lymphatic disorders, or immune incompatibilities between mother and fetus. When the effusion is isolated, meaning no other structural or chromosomal anomaly is detected, its clinical course is notoriously unpredictable. Some effusions resolve spontaneously without any intervention. Others progress relentlessly, compressing the lungs, shifting the mediastinum, and setting in motion a cascade that can end in fetal death.

The mechanics of that cascade explain why the condition is so dangerous. As fluid fills the pleural space, it compresses the developing lung tissue, which can lead to pulmonary hypoplasia, a permanent underdevelopment of the lungs that makes survival after birth impossible or profoundly compromised. The pressure also squeezes the heart, reducing cardiac output and eventually triggering hydrops, a state of widespread fluid accumulation and impending heart failure that has long been recognized as the single most ominous prognostic sign. Meanwhile, the shift of chest structures can compress the esophagus, impairing the fetus’s ability to swallow amniotic fluid and producing polyhydramnios, an excess of fluid that itself raises the risk of preterm labor. Diagnosis is typically made in the second trimester by ultrasound, which reveals an anechoic fluid collection within one or both hemithoraces.

For decades, clinicians have sought ways to intervene before the damage becomes irreversible. The simplest option is thoracentesis, in which a 20-gauge needle is inserted into the pleural cavity under ultrasound guidance and the fluid is aspirated. The problem is that the fluid tends to reaccumulate rapidly, forcing repeated needle insertions, each of which carries its own risk of infection and of preterm premature rupture of membranes, or PPROM. The standard definitive treatment is therefore pleuro-amniotic shunting. In this procedure, a trocar with an outer diameter of three millimeters is introduced through the maternal abdomen and fetal chest wall under continuous ultrasound imaging. A double-coiled pigtail silicone catheter is then deployed to create a permanent channel between the pleural space and the amniotic cavity, allowing fluid to drain continuously out of the chest and be reabsorbed by the fetal membranes.

Despite the procedure’s long history, its safety and efficacy have remained uncertain, with individual centers reporting widely varying outcomes. The new analysis, led by Enzo Lofredo Amorim and colleagues at institutions in Brazil and Italy and registered prospectively with PROSPERO, set out to resolve that uncertainty. The team searched PubMed, Embase, Scopus, and the Cochrane Central Register, screening 847 records and ultimately including ten retrospective cohort studies published between 1988 and 2022. The studies spanned Europe, North America, South America, Asia, and Oceania, and collectively involved 587 fetuses, of whom 416 underwent shunting. The weighted mean gestational age at intervention was 28.1 weeks. Bilateral effusions predominated, accounting for 76.9 percent of cases, and nearly seven in ten of the treated fetuses were male.

The pooled results tell a story of meaningful benefit tempered by real cost. Of the 416 shunted fetuses, 272 survived to discharge, yielding an overall survival rate of 65.36 percent, with individual study estimates ranging from 46.34 to 75.44 percent and only low statistical heterogeneity. Among the four studies reporting hydrops outcomes, covering 151 fetuses, resolution occurred in 94 cases, a pooled rate of 62.25 percent with essentially perfect agreement across centers, as reflected by an I-squared value of zero percent. Catheter displacement, the most common device-related complication, was recorded 62 times across nine studies, corresponding to a prevalence of 17.13 percent. Chorioamnionitis, an infection of the fetal membranes, was rare, affecting just seven of 134 fetuses in three studies, a pooled prevalence of 5.22 percent.

The obstetric toll, however, was substantial. Across six studies involving 224 fetuses, there were 155 preterm births, a pooled prevalence of 69.67 percent, meaning that roughly seven in ten pregnancies ended before 37 weeks of gestation. PPROM occurred in 17.65 percent of cases, though this estimate carried high heterogeneity, driven largely by a single cohort that reported an incidence of 82.76 percent. The authors argue that these figures underscore a crucial clinical message: pleuro-amniotic shunting should never be viewed as an isolated surgical event. The procedure effectively converts the pregnancy into a high-risk one, demanding coordinated planning among fetal medicine specialists, anesthesiologists, neonatal intensive care teams, and support staff to manage early delivery and its consequences.

The analysis also sharpened understanding of prognosis. Hydrops at diagnosis remains the most powerful negative predictor, and the included data confirmed the dichotomy: one study cited in the review found survival of 93.3 percent among non-hydropic fetuses compared with 56.0 percent among those with hydrops. Yet the most striking finding concerns reversal. When shunting succeeds in decompressing the chest and reversing hydrops in utero, the prognosis transforms dramatically. Data from one included cohort showed that hydropic fetuses whose condition resolved after drainage achieved a survival rate of 67.3 percent, approaching the outcomes of fetuses that never developed hydrops at all. The zero heterogeneity in the hydrops resolution outcome suggests a highly consistent physiological response to mechanical decompression across different global centers, lending biological plausibility to the pooled estimate.

The authors are careful to frame the strength of the evidence honestly. Using the ROBINS-I tool for non-randomized studies, all ten included cohorts were judged to carry an overall moderate risk of bias, a classification driven entirely by the confounding domain inherent to retrospective designs. Every other domain, including participant selection, intervention classification, and outcome measurement, was rated as low risk. The rarity of isolated fetal pleural effusion makes large randomized controlled trials practically and ethically difficult, so retrospective cohorts remain the best available evidence. The authors also note that expectant management may still be appropriate for mild or stable effusions, while thoracentesis, though simpler, is limited by rapid fluid reaccumulation and the cumulative morbidity of repeated needle insertions.

The bottom line for clinicians and expectant parents is a quantified trade-off. For progressive or severe isolated fetal pleural effusion, pleuro-amniotic shunting offers sustained intrathoracic decompression and a realistic chance of survival in about two-thirds of cases, with most hydropic fetuses experiencing reversal of the condition. That benefit comes bundled with a high likelihood of preterm delivery and measurable rates of device displacement and membrane rupture, which is why the authors call for multidisciplinary perinatal management as an inseparable component of the therapy. They also emphasize the need for prospective multicenter studies to refine patient selection, standardize protocols, and clarify long-term neonatal trajectories. Until such trials exist, this meta-analysis provides the most reliable benchmark yet for counseling families facing one of fetal medicine’s most consequential decisions.

Subject of Research: Perinatal outcomes of pleuro-amniotic shunting for isolated fetal pleural effusion

Article Title: Perinatal Outcomes of Pleuro-Amniotic Shunting in Isolated Pleural Effusions: Systematic Review and Meta-analysis

Article References: Amorim, E. L., Araujo Júnior, E., da Silva Lourenço, M. C., de Sousa, D. G., Ferreira, F. M., dos Santos Lobo, M. F., Provinciatto, H., Nader, E. M., Braga, A., & Granese, R. (2026). Perinatal Outcomes of Pleuro-Amniotic Shunting in Isolated Pleural Effusions: Systematic Review and Meta-analysis. Advances in Therapy. https://doi.org/10.1007/s12325-026-03809-8

Image Credits: AI Generated

DOI: 10.1007/s12325-026-03809-8

Keywords: fetal therapy, pleural effusion, pleuro-amniotic shunting, fetal hydrops, preterm birth, PPROM, meta-analysis, perinatal outcomes, fetal medicine, pulmonary hypoplasia, neonatology, systematic review